Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study

Table 3 Evolution of the eGFR in patients with eGFR below 60 ml/min/1.73m² during treatment

	Group	Gender, Age	Cirrhosis	HCV Treatment Duration	eGFR at baseline (ml/min/m²)	eGFR at W4 (ml/min/m²)	eGFR at EOT (ml/min/m²)	eGFR at SVR12 (ml/min/m²)
1	Non-TDF	Male, 66 yo	Yes	12w	59	45.3	56.9	63.9
2	Non-TDF	Male, 48 yo	Yes	24w	60	62.8	54.3	57.5
3	Non-TDF	Male, 49 yo	Yes	24w	65.9	57.1	37.8	32
4	Non-TDF	Male, 55 yo	Yes	12w	67.7	62	59.8	57.7
5	Non-boosted TDF	Male, 55 yo	Yes	24w	72.8	57.7	60.9	71.2
6	TDF+ Boosted PI	Male, 45 yo	Yes	24w	80.6	64.1	57.7	83.4

eGFR estimated glomerular filtration rate, W2 week 2 of treatment, W4, week 4 of treatment, EOT end of treatment, SVR12 end of follow up, TDF tenofovir, PI protease inhibitor, Non-TDF regimens without TDF, Non-boosted TDF regimens with TDF without boosted PI, TDF Boosted PI – regimens with TDF and boosted PI, yo years old, w week

ISSN: 1471-2334